CALIDI BIOTHERAPEUTICS INC(CLDI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLDI CALIDI BIOTHERAPEUTICS INC

Closed 02-13 16:00:00 EST

0.7826

+0.0226

+2.97%

盘后0.7826

+0.00000.00%

18:15 EST

High0.8400	Low0.7500	Vol235.09K
Open0.7500	D1 Closing0.7600	Amplitude11.84%
Mkt Cap5.61M	Tradable Cap3.01M	Total Shares7.17M
T/O184.91K	T/O Rate6.12%	Tradable Shares3.84M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CLDI","market":"US","secType":"STK","nameCN":"CALIDI BIOTHERAPEUTICS INC","latestPrice":0.7826,"timestamp":1771016400000,"preClose":0.76,"halted":0,"volume":235089,"hourTrading":{"tag":"盘后","latestPrice":0.7826,"preClose":0.7826,"latestTime":"18:15 EST","volume":11,"amount":8.7197,"timestamp":1771024503522,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.029736842105263096,"floatShares":3843300,"shares":7167700,"eps":-9.021739,"marketStatus":"Closed","change":0.0226,"latestTime":"02-13 16:00:00 EST","open":0.75,"high":0.84,"low":0.75,"amount":184911.196659,"amplitude":0.118421,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.021739,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":5,"adr":0,"exchange":"AMEX","adjPreClose":0.76,"postHourTrading":{"tag":"盘后","latestPrice":0.7826,"preClose":0.7826,"latestTime":"18:15 EST","volume":11,"amount":8.7197,"timestamp":1771024503522,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":3.207016},"requestUrl":"/m/hq/s/CLDI","defaultTab":"news","newsList":[{"id":"2610892950","title":"Calidi Biotherapeutics Presents RedTail Platform Data at AACR-IO Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2610892950","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610892950?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:02","pubTimestamp":1770901325,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. announced that it will present data on its novel RedTail platform for Bispecific T-Cell Engagers  in solid tumors at the AACR Immuno-Oncology  conference in Los Angeles, California, from February 18-21, 2026. The company will showcase how its systemically delivered virotherapy platform targets tumors and remodels the tumor microenvironment to enable T-cell engagement and localized expression of therapeutic genetic payloads. Calidi is also advancing its lead candidate, CLD-401, toward an IND submission by the end of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 12, 2026, and is sol","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDLQYRdj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014013.SGD","LU2210149790.SGD","BK4585","CLDI","SG9999014039.USD","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","BK4139","SG9999014005.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","LU0314104364.USD","NDAQ","LU2095319765.USD","BK4588"],"gpt_icon":0},{"id":"2609351794","title":"Calidi Biotherapeutics unveils RedTail platform for precision genetic medicine delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=2609351794","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609351794?lang=en_us&edition=fundamental","pubTime":"2026-02-07 07:38","pubTimestamp":1770421117,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. has outlined updates on its RedTail platform, which is designed for the precise delivery of genetic medicines to disease sites, including cancer. The company highlighted new leadership appointments and a revamped Scientific Advisory Board to support the advancement of the RedTail platform. Calidi reported progress in its pipeline, with initial data on RedTail and its CLD-401 program presented in 2025. The company stated it has reduced its debt significantly and plans to allocate around 70% of its forecasted 2026 spending to research and development. The RedTail platform leverages a vaccinia virus scaffold with a high capacity for genetic payloads and aims to improve systemic delivery of oncolytic viruses by reducing immune system recognition. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely inf","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDLqwDG7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2607085300","title":"Calidi Biotherapeutics to File IND for CLD-401 in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2607085300","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607085300?lang=en_us&edition=fundamental","pubTime":"2026-01-29 19:01","pubTimestamp":1769684501,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. announced a corporate update outlining key milestones achieved in 2025 and plans for 2026. The company reported successful execution of its 2025 priorities, including demonstrating in clinically relevant immunocompetent murine models and ex vivo human immune assays that its RedTail platform can prevent immune clearance after systemic administration and selectively replicate in tumor cells. Calidi plans to file an Investigational New Drug  application in the fourth quarter of 2026 for its first RedTail lead candidate, CLD-401, which is designed to deliver high concentrations of IL-15 superagonist to the tumor microenvironment in patients with metastatic disease. Additionally, Calidi expects to present proof-of-concept data in 2026 demonstrating the versatility of the RedTail platform, including the simultaneous delivery of tumor-localized Bi-specific T cell engagers  alongside T-cell amplifiers. The company also aims to expand the platform’s applicability to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL2PVHwL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2606224719","title":"Calidi Biotherapeutics Slashes Debt by $3.1 Million in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2606224719","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606224719?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:00","pubTimestamp":1769605220,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. announced that it reduced its term debt and notes payable, including accrued interest, by $3.1 million in 2025. The company’s debt decreased from $3.8 million at the end of 2024 to $0.7 million at the end of 2025, according to unaudited figures.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 28, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDLTytHv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014021.USD","BK4585","LU2210149790.SGD","CLDI","BK4139","BK4588","LU2095319765.USD","LU2210150020.SGD","BK4112","SG9999014005.SGD","SG9999014013.SGD","LU0314104364.USD","IE00B64PRP62.GBP","SG9999014039.USD","IE00BGHQF748.EUR","NDAQ"],"gpt_icon":0},{"id":"2606719200","title":"Calidi Biotherapeutics Inc - to File Ind for Cld-401 in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2606719200","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606719200?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:00","pubTimestamp":1769605206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nTUA5BSZLD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2606499719","title":"Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2606499719","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606499719?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:00","pubTimestamp":1769605206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nTUA5BSZLD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2592595569","title":"Calidi Biotherapeutics Director Allan Camaisa Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592595569","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592595569?lang=en_us&edition=fundamental","pubTime":"2025-12-17 08:37","pubTimestamp":1765931857,"startTime":"0","endTime":"0","summary":"Allan Camaisa, Director of Calidi Biotherapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 16, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL4ZDLr9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Calidi Biotherapeutics Director Allan Camaisa Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2584550625","title":"Calidi Biotherapeutics Hosts Exclusive Investor Webinar Featuring CEO Eric Poma","url":"https://stock-news.laohu8.com/highlight/detail?id=2584550625","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584550625?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:01","pubTimestamp":1763384495,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. will host a live investor webinar and Q&A session on November 19, 2025. During the event, CEO Eric Poma will present insights into Calidi's RedTail platform, an engineered viral therapy designed for targeted delivery of genetic medicines to metastatic tumor sites, and share recent preclinical data demonstrating its effectiveness in avoiding immune detection and delivering genetic payloads to tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL2ThLlj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4585","LU0314104364.USD","IE00BKPKM429.USD","BK4588","IE00B3QW5Z07.USD","NDAQ","BK4112","CLDI","LU2210150020.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","BK4139","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2583124465","title":"Calidi Biotherapeutics reports third quarter net loss of $5.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583124465","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583124465?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:31","pubTimestamp":1763069510,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. reported a net loss of $5.2 million for the third quarter ended September 30, 2025, compared to a net loss of $5.1 million for the same period in 2024. A non-cash charge for deemed dividend on warrants increased the net loss attributable to shareholders to $10.8 million, while there was no such charge in the prior year period. Net loss per share, basic and diluted, was $2.21, down from $7.75 in the third quarter of 2024. Research and development expenses were $2.4 million, up from $2.2 million, and general and administrative expenses were $2.7 million, down from $3.1 million in the comparable period of 2024. The company had approximately $10.4 million in cash at the end of the quarter. Calidi raised $6.9 million in gross proceeds from an underwritten public offering, bringing total gross proceeds in 2025 to $23.0 million. Key business developments included new data presentations on CLD-401, further expansion of the RedTail platform, and the establishment of ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL42YSQJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2583351265","title":"Calidi Biotherapeutics Q3 EPS $(2.21) Misses $(1.68) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583351265","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583351265?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:22","pubTimestamp":1763068926,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(2.21) per share which missed the analyst consensus estimate of $(1.68) by 31.55 percent. This is a 71.67 percent increase over losses of $(7.80) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48851012/calidi-biotherapeutics-q3-eps-2-21-misses-1-68-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Calidi Biotherapeutics Q3 EPS $(2.21) Misses $(1.68) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2583749514","title":"Calidi Biotherapeutics Raises $6.9 Million and Advances RedTail Platform Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2583749514","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583749514?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:15","pubTimestamp":1763068533,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. announced its third quarter 2025 financial results and recent operational highlights. The company raised $6.9 million in gross proceeds through an underwritten public offering with new and existing investors, extending its financial runway and bringing the total gross proceeds raised in 2025 to $23.0 million. Calidi presented new data at the Society of Immunotherapy for Cancer  annual meeting demonstrating that its CLD-401 candidate can protect from immune clearance after systemic administration and effectively express genetic medicines at tumor sites. The company expanded the capabilities of its RedTail platform, including programmable membrane targeting and the addition of multiple payloads. Calidi also established a new Scientific Advisory Board to support the development of CLD-401 and further advance the RedTail platform.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provid","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL2zRcn0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","CLDI","IE00BGHQF748.EUR","BK4112","LU0314104364.USD","BK4588","NDAQ","BK4139","BK4585","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2583514242","title":"Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2583514242","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583514242?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:15","pubTimestamp":1763068501,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA8KCKCW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2583277512","title":"Calidi Biotherapeutics Inc - Qtrly Net Loss per Share, Basic and Diluted, Was $2.21","url":"https://stock-news.laohu8.com/highlight/detail?id=2583277512","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583277512?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:15","pubTimestamp":1763068501,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA8KCKCW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2582718308","title":"Calidi Biotherapeutics Unveils Promising CLD-401 Data at SITC Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2582718308","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582718308?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:07","pubTimestamp":1762780034,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. announced new data on its lead therapeutic candidate, CLD-401, at the 2025 Society of Immunotherapy for Cancer  Annual Meeting. CLD-401, developed using Calidi's RedTail platform, is a tumor-tropic oncolytic virus designed for systemic administration that selectively replicates in tumor cells, induces immune priming at the tumor site, and expresses high levels of IL-15 superagonist in the tumor microenvironment. According to the company, preclinical syngeneic models demonstrated targeted delivery and expression of IL-15 superagonist in tumors with minimal systemic exposure. The latest results were presented at SITC 2025. Calidi is currently conducting IND-enabling studies for CLD-401 and anticipates submitting an Investigational New Drug  application by the end of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conte","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL6zwfQb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","BK4139","LU2210150020.SGD","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","CLDI","BK4588","LU2210149790.SGD","LU0314104364.USD","BK4585","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2580731748","title":"Calidi Biotherapeutics to Present RedTail Platform at SITC Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2580731748","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580731748?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:00","pubTimestamp":1762261229,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. will hold an investor event at the Society of Immunotherapy for Cancer  Annual Meeting on Friday, November 7, 2025. The company will present updates on its RedTail platform and lead candidate, CLD-401.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL2JQKhb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4588","BK4585","LU0314104364.USD","NDAQ","IE00BKPKM429.USD","BK4112","LU2210149790.SGD","LU2095319765.USD","CLDI","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2580021363","title":"Calidi Biotherapeutics Selects Matica Bio for CLD-401 Oncolytic Virus Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2580021363","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580021363?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:01","pubTimestamp":1762174907,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. has entered into a strategic partnership with Matica Biotechnology, Inc. for the development and manufacturing of CLD-401, the first lead candidate from Calidi's RedTail platform. Under the agreement, Matica Bio will provide analytical development, process development, and GMP manufacturing services to support Calidi's IND submission for CLD-401, an oncolytic virus-based therapy designed for cancer treatment. This collaboration leverages Matica Bio's expertise in viral vector manufacturing to advance Calidi's clinical-stage immuno-oncology program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire  on Nov","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL9XL7cH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2580416561","title":"Calidi Biotherapeutics Inc - Following Closing, Nova Cell Is No Longer Subsidiary of Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2580416561","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580416561?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:21","pubTimestamp":1761942088,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nFWN3WC1ON:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2580416308","title":"Calidi Biotherapeutics: on Oct 27, Enters Into Sra & Mpa, With Its Majority Owned Unit, Nova Cell","url":"https://stock-news.laohu8.com/highlight/detail?id=2580416308","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580416308?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:21","pubTimestamp":1761942088,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nFWN3WC1ON:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2580041637","title":"Calidi Biotherapeutics Inc - Sold and Transferred 22.5 Mln Shares of Nova Cell for $6 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2580041637","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580041637?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:21","pubTimestamp":1761942088,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nFWN3WC1ON:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2580141501","title":"Calidi Biotherapeutics Sells Majority Stake in Nova Cell for $6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2580141501","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580141501?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:16","pubTimestamp":1761941766,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. has completed an asset transaction with its majority-owned subsidiary, Nova Cell, Inc. Under a new Material Purchase Agreement, Calidi sold and transferred certain materials to Nova Cell, with Nova Cell also assuming specific defined liabilities and agreeing to usage restrictions. The agreement replaces a previous intellectual property assignment between the parties.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 31, 2025, and is solely responsible for the information contained ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL1k34LB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.calidibio.com","stockEarnings":[{"period":"1week","weight":-0.0975},{"period":"1month","weight":-0.3091},{"period":"3month","weight":-0.4933},{"period":"6month","weight":-0.8566},{"period":"1year","weight":-0.9578},{"period":"ytd","weight":-0.3504}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":-0.018},{"period":"3month","weight":0.0139},{"period":"6month","weight":0.0588},{"period":"1year","weight":0.1291},{"period":"ytd","weight":-0.001}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.185839},{"month":2,"riseRate":0.6,"avgChangeRate":-0.069131},{"month":3,"riseRate":0.5,"avgChangeRate":-0.101198},{"month":4,"riseRate":0.25,"avgChangeRate":-0.200168},{"month":5,"riseRate":0.25,"avgChangeRate":-0.071752},{"month":6,"riseRate":0.75,"avgChangeRate":-0.069766},{"month":7,"riseRate":0.75,"avgChangeRate":0.345315},{"month":8,"riseRate":0.25,"avgChangeRate":-0.291823},{"month":9,"riseRate":0,"avgChangeRate":-0.182897},{"month":10,"riseRate":0.75,"avgChangeRate":-0.07151},{"month":11,"riseRate":0.5,"avgChangeRate":0.188661},{"month":12,"riseRate":0.2,"avgChangeRate":-0.191351}],"exchange":"AMEX","name":"CALIDI BIOTHERAPEUTICS INC","nameEN":"CALIDI BIOTHERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CALIDI BIOTHERAPEUTICS INC(CLDI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CALIDI BIOTHERAPEUTICS INC(CLDI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CALIDI BIOTHERAPEUTICS INC,CLDI,CALIDI BIOTHERAPEUTICS INC股票,CALIDI BIOTHERAPEUTICS INC股票老虎,CALIDI BIOTHERAPEUTICS INC股票老虎国际,CALIDI BIOTHERAPEUTICS INC行情,CALIDI BIOTHERAPEUTICS INC股票行情,CALIDI BIOTHERAPEUTICS INC股价,CALIDI BIOTHERAPEUTICS INC股市,CALIDI BIOTHERAPEUTICS INC股票价格,CALIDI BIOTHERAPEUTICS INC股票交易,CALIDI BIOTHERAPEUTICS INC股票购买,CALIDI BIOTHERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CALIDI BIOTHERAPEUTICS INC(CLDI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CALIDI BIOTHERAPEUTICS INC(CLDI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction